The Aeson Total Artificial Heart helps three heart failure patients with pulmonary hypertension become heart transplant-eligible, The Journal of Heart and Lung Transplantation, February 5, 2025

Three heart failure patients with pulmonary hypertension (WHO Group II) became eligible for heart transplants after receiving the Aeson Total Artificial Heart, which effectively took place after 243, 155 and 109 days respectively. This innovative device, implanted with the help of the advanced Carmat system, replaces the heart’s ventricles and maintains continuous blood circulation, stabilizing […]

The Aeson Total Artificial Heart helps three heart failure patients with pulmonary hypertension become heart transplant-eligible, The Journal of Heart and Lung Transplantation, February 5, 2025 Read Post »

Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients, The Lancet, February 20, 2025

An article titled “Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients”, was published in The Lancet on February 20, 2025. It reports on discussions held between a group of international experts at the 20th Global CardioVascular Clinical Trialists Forum, CVCT (Washington DC, USA), patients’ representatives, and members

Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients, The Lancet, February 20, 2025 Read Post »

A proposal to involve people living with rare and complex conditions in the development of clinical practice guidelines, Patient Education and Counseling, February 19, 2025

The objective of the study published on February 19, 2025 as a Journal pre proof on Patient Edcuation and Counseling (§), is to develop a proposal to involve people living with rare and complex conditions in the development of clinical practice guidelines, based on a systematic review of qualitative literature (64 publications). The authors offer

A proposal to involve people living with rare and complex conditions in the development of clinical practice guidelines, Patient Education and Counseling, February 19, 2025 Read Post »

Medication Non-Adherence in Patients with Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association (PHA) Registry (PHAR), Annals of the American Thoracic Society, February 18, 2025

Medication non-adherence in pulmonary arterial hypertension (PAH) can significantly impact patient outcomes, yet its prevalence and consequences remain understudied. This multi-center registry analysis examined self-reported non-adherence rates among pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (CTEPH) patients, identifying key socioeconomic predictors and associated healthcare outcomes. Using data from the Pulmonary Hypertension Association Registry (PHAR),

Medication Non-Adherence in Patients with Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association (PHA) Registry (PHAR), Annals of the American Thoracic Society, February 18, 2025 Read Post »

The US Food and Drug Administration (FDA) has approved clinical trials to transplant organs from genetically modified pigs into people with kidney failure

The US Food and Drug Administration (FDA) has approved pioneering clinical trials by two biotech firms to evaluate the transplantation of kidneys from genetically engineered pigs into human patients with renal failure. This breakthrough authorization could mark a significant step toward addressing the chronic shortage of human organs for transplant. Until now, such transplants were

The US Food and Drug Administration (FDA) has approved clinical trials to transplant organs from genetically modified pigs into people with kidney failure Read Post »

Deep Learning-Based Pulmonary Hypertension Screening Algorithm Using a Digital Stethoscope, Journal of the American Heart Association, February 4, 2025

Pulmonary hypertension often goes undiagnosed in part because of low suspicion and screening tools not being easily accessible. A deep learning study, published on the Journal of the American Heart Association, has developed a novel screening method for pulmonary hypertension using digital stethoscope recordings (phonocardiograms). By analyzing approximately 6,000 PCG recordings with echocardiogram data, researchers

Deep Learning-Based Pulmonary Hypertension Screening Algorithm Using a Digital Stethoscope, Journal of the American Heart Association, February 4, 2025 Read Post »

Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies, European Respiratory Journal, January 30, 2025

This post-hoc, exploratory pooled analysis, published on January 30, 2025, on the European Respiratory Journal, combines data from the Phase 2 PULSAR and Phase 3 STELLAR studies on sotatercept, both international, multicentre, randomised, double-blind, placebo-controlled trials in pulmonary arterial hypertension patients. Out of 429 randomised patients, 237 received sotatercept and 192 placebo. After 24 weeks,

Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies, European Respiratory Journal, January 30, 2025 Read Post »

The Dutch Pulmonary Hypertension Association has contributed financially to the RECOMPENSE Phase 4 study on sotatercept conducted by the Amsterdam University Medical Center

The Dutch Pulmonary Hypertension Association, Stichting Pulmonale Hypertensie, has contributed financially with an amount of € 40.000 the RECOMPENSE – Right VEntricular COMPENsation with SotatercEpt – Phase 4 study conducted by the Amsterdam UMC. This research aims to investigate sotatercept’s effects on right ventricular function. Background Several large international studies have already been conducted in

The Dutch Pulmonary Hypertension Association has contributed financially to the RECOMPENSE Phase 4 study on sotatercept conducted by the Amsterdam University Medical Center Read Post »

Novel PET approach may help to identify early signs of pulmonary arterial hypertension, Journal of Nuclear Medicine, January 2025

A new molecular imaging technique called18F-FAPI Positron Emission Tomography (PET) has been shown to be able to detect the first signs of the tissue remodeling typical of patients with pulmonary arterial hypertension and could provide physicians with an early marker for disease progression. This approach has the potential to pave the way for more personalized

Novel PET approach may help to identify early signs of pulmonary arterial hypertension, Journal of Nuclear Medicine, January 2025 Read Post »

Prognostic relevance of exercise pulmonary hypertension: results of the multicentre PEX-NET Clinical Research Collaboration, European Respiratory Journal

The PEX-NET (Pulmonary Haemodynamics during Exercise Network) registry enrolled patients who underwent clinically indicated right heart catheterisations both at rest and ergometer exercise from 23 PH centres worldwide. The aim of the study was to explore the prognostic relevance of exercise haemodynamics and its added value to resting haemodynamics are missing. The study finds that

Prognostic relevance of exercise pulmonary hypertension: results of the multicentre PEX-NET Clinical Research Collaboration, European Respiratory Journal Read Post »

From basic scientific research to the development of new drugs for pulmonary arterial hypertension: insights from activin-targeting agents, Breathe, January 21, 2025

This article, authored by Prof. Christophe Guignabert, Director of Research at Inserm – Université Paris-Saclay, France, explores the pathophysiology of pulmonary arterial hypertension, focusing on key mechanisms of disease progression. It notes that in the past three decades, significant advancements in treatment, with 12 new drugs, have improved patients’ quality of life, reduced short-term mortality

From basic scientific research to the development of new drugs for pulmonary arterial hypertension: insights from activin-targeting agents, Breathe, January 21, 2025 Read Post »

Simulation of clinical trials of oral treprostinil in pulmonary arterial hypertension using a virtual population, Nature Briefing Journal, January 15, 2025

The study published recently in the Nature Briefing Journal explores using mathematical modeling to address drug development challenges in pulmonary arterial hypertension. Researchers developed a quantitative systems pharmacology (QSP) model in the context of oral treprostinil clinical studies to predict changes in pulmonary vascular resistance and six-minute walk distance by creating a virtual patient population

Simulation of clinical trials of oral treprostinil in pulmonary arterial hypertension using a virtual population, Nature Briefing Journal, January 15, 2025 Read Post »

Only a minority of US patients receive pulmonary arterial hypertension-specific prescriptions from a pulmonary hypertension center, reveal the findings of a recent study

The authors of this article, published on the American Journal of Respiratory and Critical Care Medicine on January 13, 2025 say that guidelines recommend patients with pulmonary arterial hypertension be referred to pulmonary hypertension centers, but little is known about where care is actually delivered in the United States. Prescription patterns were used to estimate

Only a minority of US patients receive pulmonary arterial hypertension-specific prescriptions from a pulmonary hypertension center, reveal the findings of a recent study Read Post »

Pathway to care, treatment and disease burden of pulmonary arterial hypertension: a real-world survey of physicians and patients in Latin America, British Medical Journal, December 31, 2024

An article published on the British Medical Journal Open on December 31, 2024, titled “Pathway to care, treatment and disease burden of pulmonary arterial hypertension: a real-world survey of physicians and patients in Latin America”, reports on the findings of a cross-sectional survey with retrospective data collection. A total of 246 physicians, from University/teaching hospitals,

Pathway to care, treatment and disease burden of pulmonary arterial hypertension: a real-world survey of physicians and patients in Latin America, British Medical Journal, December 31, 2024 Read Post »

Stronger Together: Celebrating the Pulmonary Hypertension Community’s 2024 Milestones

The year 2024 has seen significant progress in the fight against pulmonary hypertension, marked by critical milestones across research, clinical care, advocacy, awareness, and patient engagement, with an unprecedented level of patient involvement in scientific discourse. As we head into 2025 with all that has been achieved we are well positioned in furthering our mission!

Stronger Together: Celebrating the Pulmonary Hypertension Community’s 2024 Milestones Read Post »

Challenges in implementing the new European clinical guidelines in Central and Eastern Europe: a review from the Polish Heart Journal 

An article published in the Polish Heart Journal on December 23, 2024, titled “Emerging therapies and new directions in the treatment of pulmonary arterial hypertension” points out that the integration of novel therapeutic protocols into everyday medical practice faces various obstacles, particularly when considering regional differences in implementation. The paper draws insights from medical experts

Challenges in implementing the new European clinical guidelines in Central and Eastern Europe: a review from the Polish Heart Journal  Read Post »

Proud to celebrate the 14 live webinars we have organised since the series launched in June 2023! A huge thank you to all our speakers and participants!

The Alliance for Pulmonary Hypertension (AfPH) recently concluded its 14th webinar, marking the culmination of an educational initiative that began in June 2023. These virtual gatherings brought together internationally renowned experts in pulmonary hypertension, who shared their expertise on a comprehensive range of topics crucial to advancing patient care and quality of life. The diverse

Proud to celebrate the 14 live webinars we have organised since the series launched in June 2023! A huge thank you to all our speakers and participants! Read Post »

Update on the Pulmonary Vascular Research Institute (PVRI)’s Pulmonary Hypertension Global Survey (PH GPS)

Almost 4,000 patients and carers across 85 countries completed Phase 1 of the Pulmonary Hypertension Global Patient Survey (PH GPS). The survey was translated into 24 languages and launched in October 2023. The survey was written by a multidisciplinary panel of pulmonary hypertension specialists and patient group advocates from the pulmonary hypertension associations of Europe,

Update on the Pulmonary Vascular Research Institute (PVRI)’s Pulmonary Hypertension Global Survey (PH GPS) Read Post »

Special issue of “Transplant International” addresses race, gender, socioeconomic and geographic disparities in transplantation

Transplant International has published a special issue of its journal on “Diversity, Equity, and Inclusion in Transplantation”. This issue presents a collection of studies that examine inequities in transplantation related to race, gender, socioeconomics, and geography, providing evidence and insights into these persistent disparities. Download the pdf of the special issue of Transplant International at

Special issue of “Transplant International” addresses race, gender, socioeconomic and geographic disparities in transplantation Read Post »

AI Model for Depression Diagnosis Developed in Finland: A Potential Breakthrough for Accessible and Early Mental Health Care

Researchers at Kaunas University of Technology, Finland, have developed an artificial intelligence model that combines speech and brain activity data to diagnose depression with an accuracy of 97.53 percent. This innovative approach, detailed in an article for Brain Sciences dated October 15, 2024, leverages both electroencephalogram signals and voice recordings to assess emotional states more

AI Model for Depression Diagnosis Developed in Finland: A Potential Breakthrough for Accessible and Early Mental Health Care Read Post »

TRANSLATE »
Scroll to Top